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Dyslipidaemia, statins and
rheumatoid arthritis
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Cardiovascular morbidity and mortality
are enhanced in rheumatoid arthritis (RA)
and there is increasing evidence that this
is due to the inflammatory process as well
as to an increased prevalence of tradi-
tional cardiovascular risk factors, such as
dyslipidaemia.1–3
DYSLIPIDAEMIA IN ESTABLISHED AND
FUTURE PATIENTS WITH RA
Several investigators have indeed demon-
strated dyslipidaemia, definedashigher total
cholesterol and/or triglycerides and/or lower
high-density lipoprotein (HDL) cholesterol
levels in comparison to control subjects, in
RA and thisappears tobethe consequence of
systemic release of inflammatory cytokines
such as tumour necrosis factor (TNF)a,
interleukin (IL)1 and IL6, leading to a
proatherogenic state with insulin resistance,
endothelial cell activation and hypercoagu-
lation as other consequences.
The dyslipidaemia in RA is dependent
on disease activity, ie, a higher disease
activity is associated with lower total
cholesterol levels and even more depressed
HDL cholesterol levels, leading to a higher
(ie, unfavourable) atherogenic index.4
Moreover, it appears that dyslipidaemia
is already present in early RA and the
question arises whether or not this
phenomenon starts in the preclinical
phase of RA. Hence, we investigated the
lipid profile over time and its relationship
with inflammation and serological mar-
kers, in subjects who later developed RA.5
The lipid profile was determined in 1078
serial blood bank samples, of 79 blood
donors who later developed RA. These
samples were compared with 1071 control
samples of unselected blood donors,
matched for age and sex. The samples of
future patients with RA displayed, on
average, 4% higher total cholesterol, 9%
lower HDL cholesterol and 17% higher
triglyceride levels compared to matched
controls (p(0.05), at least 10 years before
the onset of RA symptoms. Although the
differences in the various lipid values were
small they may have clinical relevance, in
the light of results from other studies. For
instance, in a placebo-controlled study
with fibrates, the differences of the lipid
values between the active treatment and
the placebo group were similar to the
observed differences in our study and the
individuals treated with fibrates had
ultimately a more than 20% risk reduction
for cardiovascular disease.6
HDL CHOLESTEROL
As the observed differences in lipid levels
between future patients with RA and the
control subjects were only partially
explained by the differences in C-reactive
protein (CRP) levels, alternative explana-
tions are required. A tempting idea is that
a (marginally) deteriorated lipid profile
may render a person more susceptible to
inflammation or inflammatory diseases.
In other words, one or more of the
examined lipids could have a regulatory
effect on inflammation. It is well known
that contact-mediated activation of
monocytes by stimulated T lymphocytes
is important for the production of TNFa
and interleukin 1 in RA. Hyka et al
demonstrated, in an experimental model,
the ability of apolipoprotein A-I (apo A-I),
the protein part of HDL cholesterol, to
inhibit this inflammatory response.7 It
appeared that apo A-I hampers the bind-
ing of T lymphocytes to monocytes with
subsequent abolishing of TNFa and IL1
production. In addition to the contact
mediated inhibition of monocytes, HDL
cholesterol inhibits the expression of vascu-
lar cell adhesion molecule 1 (VCAM-1) and
intercellular adhesion molecule 1 (ICAM-1)
in TNFa stimulated human cells.8
Altogether these data indicate an active
modulating role of lipids in inflammation.
It is important to realise that inflamma-
tion itself might alter the properties of
HDL cholesterol Atherosclerosis starts
when low-density lipoprotein (LDL) cho-
lesterol infiltrates the artery wall and is
oxidised by reactive oxygen species to
oxidised LDL cholesterol (ox-LDL choles-
terol). Ox-LDL cholesterol leads to phos-
pholipid release, activating endothelial
cells, thereby initiating an inflammatory
process that leads to the formation of
foam cells and subsequent fatty streaks.
Normal HDL cholesterol exerts its anti-
atherogenic role by protecting LDL cho-
lesterol from oxidation,9 in addition to the
inhibition of the expression of adhesion
molecules and its role in the reverse
cholesterol transport. This anti-inflamma-
tory HDL cholesterol can be distinguished
from the so-called proinflammatory HDL
cholesterol which does not have these
properties and actually may promote
inflammation.10 Recently, McMahon and
colleagues showed that proinflammatory
HDL cholesterol was detected more often
in patients with RA (n = 48) than in
control subjects,(n = 72) (ie, 20% vs 4%,
respectively).11 This impairment of the
ability of HDL cholesterol to prevent
oxidation of LDL cholesterol might pre-
dispose RA to development of cardiovas-
cular disease and effective antirheumatic
treatment might restore the functional
capacities of HDL cholesterol.12
LIPID LOWERING AGENTS AND (THE
DEVELOPMENT OF) RA
In view of the above-mentioned interplay
between lipids and inflammation, it is of
interest to study the effect of lipid
modulation by cholesterol lowering
agents, particularly statins, in inflamma-
tory situations. It has been demonstrated
that several statins significantly increase
HDL cholesterol and apo A-I through
upregulation of apo A-I synthesis, in vitro
as well as in vivo.13 14 As a consequence,
this could lead to modulation of inflam-
matory processes.
A pivotal feature of RA is inflammation
associated bone destruction and as recent
data indicate that statins are potent
inducers of bone morphogenic protein and
osteoclastogenesis inhibitors,15 Funk et al
investigated their potential bone protective
properties.16 In an experimental rat arthritis
model, simvastatin was given to female
Lewis rats 4 days before or 8 days after
induction of arthritis and simvastatin
prevented early and late joint inflamma-
tion and this was associated with a
decrease in articular macrophage influx.
Moreover, simvastatin inhibited periarticu-
lar bone destruction occurring late in the
course of disease and preserved periarticular
bone mineral density. These results suggest
that statins may be therapeutically useful
in preserving periarticular bone in RA joints
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via suppression of inflammation-induced
bone resorption.
These properties of statins warranted
further clinical investigation and after a
small clinical investigation with simvas-
tatin revealed an impressive 50% reduc-
tion of disease activity in 9 out of 10
patients,17 a double-blind placebo-con-
trolled trial with another statin (atorvas-
tatin) in 116 patients with RA was
conducted.18 These patients were either
treated with atorvastatin 40 mg or pla-
cebo for 6 months, in addition to their
disease-modifying antirheumatic drug
(DMARD) therapy. At 6 months, there
was a modest, but significant, improve-
ment of the disease activity (0.5 point on
the disease activity 28 score) in the
atorvastatin group compared to the pla-
cebo group with a CRP and erythrocyte
sedimentation rate decline of 50% and
28%, respectively. Obviously, there is now
a need for larger investigations with
longer follow-up, that investigate if, and
to what extent (and at what dose), statins
can prevent the bone destruction in RA.
Altogether, lipids and alteration of the
lipid profile by statins have the potential
to modulate inflammatory features of RA
and a tempting hypothesis is that they
therefore could also have a role in the
development of RA or other inflamma-
tory disorders. For instance, the West of
Scotland Coronary Prevention Study
(WOSCOPS) revealed 30% less new onset
diabetes in the men treated with pravas-
tatin vs the placebo-treated persons.19 One
of the explanations may be that pravas-
tatin lowers the levels of IL6 and TNFa
resulting in a decreased lipolysis in adi-
pose tissue and less insulin resistance, and
recently it was demonstrated that pravas-
tatin additionally increases the levels of
adiponectin, an adipose tissue derived
cytokine with anti-atherosclerotic and
insulin-sensitising functions.20
Likewise a lower incidence of RA would
also be expected in ‘‘normal’’ subjects
receiving lipid lowering drugs vs those
who did not, in controlled clinical trials
investigating these drugs. Unfortunately,
this topic has not yet been addressed in
such trials. However, a recent epidemio-
logical investigation has shed some light
on this topic.21
The General Practice Research Database
was used in this nested case-control study
and this database was founded in 1987
and presently encompasses 5 million UK
residents who are representative of the
UK population. The present study period
was 10 years (until 31 December 2001)
and three groups of subjects aged 40 to 89
years were identified from the database:
(a) patients exposed to a statin or other
lipid lowering drugs, (b) subjects with a
hyperlipidaemia diagnosis with no lipid-
lowering drugs and (c) a random sample of
25 000 persons with no hyperlipidaemia
nor prescriptions for lipid-lowering drugs.
From the database population incident
cases of RA were identified and up to four
controls per case, matched on age, sex,
general practice, years of history in the
database and index date were selected.
Conditional logistic regression techniques
were used to investigate the effects of
hyperlipidaemia and statins on the devel-
opment of RA. A total of 313 incident
cases of RA were identified and matched
with 1252 controls. RA cases had hyperli-
pidaemia more often than controls, and
there was a 30% risk increase for RA in
those persons with untreated hyperlipi-
daemia (odds ratio (OR) 1.33, 95% CI 0.95
to 1.86) and persons with no hyperlipi-
daemia had a 30% risk decrease for RA
(OR 0.68, 95% CI 0.50 to 0.91).
Compared to persons with hyperlipi-
daemia but no statin, current statin use
reduced the risk for the development of
RA with 30% (those with statin and
hyperlipidaemia) to 40% (those with
statin without hyperlipidaemia, albeit
that this reduction did not reach statis-
tical significance). Subgroup analyses
revealed no important differences among
the three most commonly prescribed
statins (ie, simvastatin, pravastatin and
atorvastatin). Remarkably, lipid lowering
drugs other that statins were not asso-
ciated with a decreased risk. This might be
due to too low a patient number treated
with these drugs, a too limited effect on
the lipid profile or the absence of anti-
inflammatory properties of these drugs.
This investigation reveals two impor-
tant points: (1) the association between
hyperlipidaemia and the development of
RA, which is in line with the findings of
van Halm et al5 and (2) that statins are
protective against development of RA in
those with hyperlipidaemia.
Future studies will have to address
whether or not statins really protect
against the development of RA or if they
only delay disease onset.
CONCLUSIONS
There is a growing body of evidence
indicating relationships between dyslipi-
daemia and (the development) of RA. At
least 10 years before disease onset there is
a disturbed lipid profile and future studies
should elucidate if this dyslipidaemia
renders a person more susceptible for the
development of RA, through proinflam-
matory mechanisms or if there is a
coupled genetic or socioeconomic back-
ground. As a consequence targeting dysli-
pidaemia may influence inflammation
and the development of inflammatory
disorders. Indeed, the literature suggests
that statins may have a moderate disease-
modifying effect in RA and this is, at least
partly, independent from their cholesterol
lowering properties and ascribed to their
pleiotropic anti-inflammatory actions.
Very recently, it appeared that these drugs
might also prevent (or retard) the devel-
opment of RA.
The challenge is obviously to translate
the (presumed) RA preventing effect of
statins into clinical practice. Over the past
few years there has been a continuing
debate as to whether or not a polypill that
combines aspirin, a statin for lowering
cholesterol and an angioconverting
enzyme inhibitor with a thiazide to lower
blood pressure should be given to all
persons with an increased cardiovascular
risk (eg, elderly persons).22 23 Presently, the
first international placebo-controlled trial
has been initiated,24 which will be fol-
lowed by large-scale placebo-controlled
investigations when the first results
demonstrate that the polypill is tolerable
and efficacious. Perhaps, the combination
of all these trials might show a favourable
effect of statin/polypill on the incidence
of inflammatory diseases such as RA,
albeit that the number of incident cases
might still be too low.
The clinical use of statins is more
realistic in the context of cardiovascular
risk management in RA. When lipid
lowering therapy is necessary, statins are
preferred over other lipid lowering drugs,
as they not only target dyslipidaemia but
also have anti-inflammatory properties
and this is important as nowadays cardi-
ovascular risk management in RA should
be targeted at the inflammatory process
as well as the cardiovascular risk factors.25
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